News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Clinical - Phase I
Sunshine Biopharma, Inc. Announces That The Initial Manufacturing Sample Of Its Anticancer Compound Adva-27a Meets Biological Specifications Paving The Way For Clinical Trials 8/4/2015
DURECT Corporation (DRRX) Announces Second Quarter 2015 Financial Results And Update Of Programs 8/4/2015
Nivalis Therapeutics Reports Financial Results For The Second Quarter 2015 8/4/2015
Charleston Laboratories, Inc. Initiates Patient Enrollment In A Phase 1 Study Of Charleston's Second Product, CL-H1T 8/3/2015
Protalix Biotherapeutics, Inc. (PLX) Reports Positive Phase I Clinical Study Results For PRX-106 Oral Anti-TNF 8/3/2015
BeiGene Co.,Ltd Receives Approval To Initiate Clinical Trials In China With BGB-283 For Solid Tumor Cancers 8/3/2015
Cidara Therapeutics (CDTX) Initiates Phase 1 Study Of Lead Antifungal Product Candidate CD101 IV 8/3/2015
Medivir (MVRBF) Announces That Janssen Pharmaceutical Has Started A Phase I Study To Evaluate The Effect Of Simeprevir And Odalasvir On AL-335 Pharmacokinetics 8/3/2015
Daiichi Sankyo, Plexxikon Inc.'s Rare Disease Drug Shows Promise in Phase I Study 7/30/2015
Suzhou Connect Reports Positive Results For Trial Of Autoimmune Drug 7/30/2015
ViaCyte, Inc. (Formerly Known as Novocell, Inc.) Announces Second Clinical Trial Site At University of Alberta 7/30/2015
Kyowa Hakko Kirin And Bristol-Myers Squibb (BMY) Announce Immuno-Oncology Clinical Collaboration Studying Mogamulizumab And Opdivo (Nivolumab) In Advanced Solid Tumors In The U.S. 7/30/2015
GlaxoSmithKline (GSK) CEO Confident Investors Will Be Pleased With Pipeline on Nov. R&D Day 7/30/2015
Medivir (MVRBF) Announces Start Of A Phase I Clinical Trial Of The Nucleotide Polymerase Inhibitor AL-704 For Treatment Of Hepatitis C 7/29/2015
University of Colorado Cancer Center And Loxo Oncology (LOXO) Announce Publication That Provides Clinical Validation For LOXO-101 Against TRK Fusion Cancer 7/28/2015
Human Study Shows Remedy Pharmaceuticals, Inc.’ CIRARA Is Key To Preventing Brain Swelling In Stroke 7/28/2015
Moerae Initiates Lipopolysaccharide (LPS) Challenge Study Of Inhaled MMI-0100 For Pulmonary Disease Following Encouraging Safety And Tolerability Observed In Single Ascending Dose Phase 1 Study 7/28/2015
OncoMed Pharmaceuticals, Inc. (OMED) Initiates Phase I Clinical Trial For Anti-RSPO3 Antibody 7/28/2015
Embattled Vitae Pharma (VTAE) and Boehringer Ingelheim Relationship Takes Another Blow, Drops BACE Inhibitor Program for Alzheimer’s 7/27/2015
ZIOPHARM Oncology (ZIOP.OB) Announces Orphan Drug Designation For Ad-RTS-Hil-12 In The Treatment Of Malignant Glioma 7/27/2015
Inovio Pharmaceuticals (INO) Initiates Clinical Trial Of INO-5150 DNA Immunotherapy For Prostate Cancer 7/27/2015
Vaxin, Inc. First-in-Man Phase I Clinical Trial Initiated In Chronically Infected Hepatitis B Patients 7/27/2015
Cardiome Pharma Corp. (COM.TO) Partner Eddingpharm (Cayman) Inc. To Initiate BRINAVESS Phase I Study In China 7/24/2015
Encouraging Results Of AXON's Tau Vaccine Advance Alzheimer's Therapy 7/23/2015
Portage Biotech's Biohaven Announces IND Filing For Bhv-0223 For Phase 1 Clinical Testing 7/23/2015
Lpath (LPTN) Announces Plan To Begin Lpathomab Clinical Trial 7/23/2015
NeuralStem Inc. Release: US District Court Rules In Favor Of Neuralstem In Patent Infringement Case 7/23/2015
Sarepta (SRPT) Announces The New England Journal of Medicine Publication Of Phase I Clinical Data Of Marburg Drug Candidate, AVI-7288, Supporting Safety Of The Pmoplus Platform 7/23/2015
ANGLE plc Preliminary Results For The Year Ended 30 April 2015 7/23/2015
Biogen (BIIB) Presents New Data From Phase IB Study Of Investigational Alzheimer’s Disease Treatment Aducanumab (BIIB037) At Alzheimer’s Association International Conference 2015 7/22/2015
TRACT Therapeutics Completes Phase I Safety Trial Using A Patient’s Immune Cells To Prevent Organ Rejection 7/22/2015
Ironwood (IRWD) Progresses SGC Stimulator Platform With Positive Top-Line Phase I Data On IW-1973 7/22/2015
Addex Therapeutics (ADXN.SW) Dipraglurant Dosed In First Subject In Receptor Occupancy Study In Collaboration With Johns Hopkins University And With Funding From The Michael J. Fox Foundation 7/22/2015
Kolltan Pharmaceuticals Inc. To Present KTN0158 Preclinical Data At The European Cancer Congress 2015 7/22/2015
Aratana Therapeutics (PETX) Provides Update On Monoclonal Antibody Products 7/22/2015
Anaheim Clinical Trials (ACT) Achieves Another Milestone In Japanese Bridging Studies 7/22/2015
Novavax, Inc. (NVAX) Announces Positive Top-Line Data From Phase I Ebola Vaccine Trial On WHO Teleconference 7/21/2015
Isis Pharma (ISIS) Initiates Clinical Study Of ISIS-HTT Rx In Patients With Huntington's Disease 7/21/2015
Cerulean Pharma Inc. (CERU) Announces First Patient Dosed In Phase Ib Trial Of CRLX101 In Combination With Weekly Paclitaxel In Relapsed Ovarian Cancer 7/21/2015
Beike Bio-Technology Co. Ltd Publishes New Research Finding Adult Mesenchymal Stem Cells Safe And Effective In Acute Myocardial Infarction 7/21/2015
Replicel Life Sciences Receives Two Important Approvals For Dermal Rejuvenation Clinical Trial 7/21/2015
MGB Biopharma Limited Commences Phase I Clinical Trial With Oral Formulation Of MGB-BP-3 For The Treatment Of Multi-Resistant Clostridium Difficile Infections 7/21/2015
Peritech Pharma’s Novel Hemorrhoids Treatment Shown Superior To Preparation-H In Pivotal Trial 7/21/2015
OrbusNeich Announces Enrollment Of First Patient In China Recovery Study 7/20/2015
DelMar Pharmaceuticals Expands GBM Clinical Trial With Fifth Clinical Trial Site Added In Denver, Colorado 7/20/2015
aTyr Pharma Announces Transitions In Clinical Development & Operations 7/20/2015
CEL-SCI (CVM) Expands Its Phase I Study For Treatment Of Anal Warts In HIV/HPV Co-Infected Patients With Addition Of 2nd Site At University of California, San Francisco (UCSF) 7/20/2015
THERAVECTYS To Present Detailed Phase I/II Results From The First-Ever Lentiviral-Vector Based Therapeutic Vaccine Trial At The 2015 Towards An HIV Cure Symposium 7/20/2015
InnaVirVax Presents Highly Encouraging Results Of Its First Clinical Study On VAC-3S Immunotherapy For HIV 7/20/2015
Adaptimmune’s NY-ESO-1 TCR-Engineered T-Cells Demonstrate Durable Persistence, Clinical Activity And Tolerability In Clinical Study In Multiple Myeloma Patients 7/20/2015
C2N And AbbVie (ABBV) Announce FDA Orphan Drug Designation Of C2N-8E12 (ABBV-8E12) For The Treatment Of Progressive Supranuclear Palsy 7/17/2015
Cellecta, Inc. Receives NIH SBIR Grant To Develop Validated Crispr Knockout Library Of Guide RNA (sgRNA) Sequences 7/17/2015
EyeGate Pharma Treats First Patient In Phase Ib / 2a Trial Of EGP-437 In Macular Edema 7/14/2015
Blaze Bioscience Inc. Announces Open Enrollment For Phase 1 Clinical Trial Of Tumor Paint BLZ-100 In Patients With Solid Tumor Cancers 7/14/2015
BeiGene Co.,Ltd Doses First Patient In Phase Ib Study Of BGB-283, A Novel Second Generation B-RAF Inhibitor 7/14/2015
Blueprint Medicines (BPMC) Receives FDA Authorization To Proceed With Clinical Trials For Two Drug Candidates 7/13/2015
Cleave Biosciences Receives Orphan Designation From FDA For CB-5083 For Treatment Of Multiple Myeloma 7/13/2015
Cord Blood Registry Release: Groundbreaking Clinical Trial To Assess Use Of Newborn Stem Cells In The Treatment Of Pediatric Stroke 7/13/2015
Exelixis (EXEL) Announces Start Of Phase I Trial Of Cabozantinib In Combination With Nivolumab Or Nivolumab Plus Ipilimumab In Patients With Advanced/Metastatic Urothelial Carcinoma And Other Genitourinary Tumors 7/13/2015
Five Prime (FPRX) Initiates Patient Dosing In Phase I/II Clinical Trial Evaluating FPA008 In Pigmented Villonodular Synovitis 7/13/2015
Cleveland Biolabs Inc. (CBLI) Announces Results Of Phase 1 Study Of CBLB612 In Russian Federation 7/13/2015
Adocia Initiates Two Clinical Studies On Its Combination Of Long-Acting Insulin Glargine And Fast-Acting Insulin Lispro, Biochaperone Combo 7/10/2015
Tyrogenex, Inc. Presents Phase I Study Of X-82 For Wet AMD At The International Symposium On Ocular Pharmacology And Therapeutics Clinical 7/9/2015
DelMar Pharmaceuticals To Present Updated Phase I/II Clinical Data On Val-083 In The Treatment Of Refractory Glioblastoma Multiforme At GBM2015: 2nd International Symposium On Clinical And Basic Investigation In Glioblastoma 7/9/2015
BIO2015 EXCLUSIVE: BioSpace (DHX)’s Insider Profile of Neovacs SA 7/9/2015
Johnson & Johnson (JNJ) HIV Vaccine Blocks Virus in 50% of Monkeys, Soon to Start Human Trial in 400 7/9/2015
Arrowhead Research Corporation (ARWR) Receives Regulatory Clearance For ARC-AAT Phase 1 In The United Kingdom And New Zealand 7/8/2015
AXON Neuroscience’s Vaccine To Halt Alzheimer’s Finishes Phase 1 Clinical Trial 7/8/2015
Curetis Initiates Next Phase Of Unyvero U.S. FDA Trial In Lower Respiratory Tract Infections 7/8/2015
EXCLUSIVE: DNAnexus, Stanford University Genomic Catalog Will Accelerate Science in the Field, Says CEO 7/8/2015
FDA Bestows Breakthrough Therapy Designation on Dyax Corp. (DYAX)'s HAE Drug As Suitors Circle 7/7/2015
CureVac Announces Phase I/IIa Clinical Study Data Of Its mRNA Cancer Immunotherapy In Prostate Cancer Published In The Journal For Immunotherapy Of Cancer 7/7/2015
Abide Therapeutics Announces First Subject Dosed In First-In-Human Clinical Study Of ABX-1431, An Investigational Endocannabinoid System Modulator 7/7/2015
Enzymotec Announces Investigator Initiated Clinical Trial Of Vayarin In Managing ADHD In Children With Epilepsy 7/7/2015
Dyax Corp. (DYAX) Receives FDA Breakthrough Therapy Designation For DX-2930 For Prevention Of Attacks Of Hereditary Angioedema 7/7/2015
Blaze Bioscience Inc.’s BLZ-100 Receives Orphan Drug Designation From FDA For Brain Cancer 7/7/2015
WCCT Global Completes Multiple Ethnobridging Studies At Phase I CPUs 7/7/2015
XBiotech USA (XBIT) Treats First Patient In Phase I/II Clinical Study Of Novel True Human Therapeutic Antibody For Treating Serious Infections Due To Staphylococcus Aureus 7/6/2015
Catabasis Pharmaceuticals, Inc. Receives FDA Fast Track Designation For CAT-1004 For The Treatment Of Duchenne Muscular Dystrophy 7/6/2015
PhytoTech Medical Ltd (ASX:PYL) Oral Formulations Advance Towards Phase 1 Clinical Trials 7/6/2015
Immunovaccine Inc. Publishes Clinical Results With DPX-Survivac In Combination With An Immune-Modulating Compound 7/2/2015
Avexxin Completes Phase I/IIA Study In Psoriasis And Achieves Proof-Of-Concept In Man With Its Compound AVX001 In A Topical Formulation 7/2/2015
Arrowhead Research Corporation (ARWR) Initiates Dosing Of ARC-AAT In Patients With Alpha-1 Antitrypsin Deficiency 7/2/2015
EXCLUSIVE: Pediatric Patients Could Benefit Most From New Oncoceutics Cancer Drug, Says Exec 7/2/2015
Provectus Biopharmaceuticals Inc.’ Data On PV-10 For Chemoablation Of Liver Cancers Presented At ESMO 17th World Congress On Gastrointestinal Cancer 7/2/2015
Vitae Pharma (VTAE)’ Diabetes Drug Fails Mid-Stage Trial, the Second Drug in Less Than Six Months to Fail 7/1/2015
Rock Creek Pharmaceuticals Reports Human Proof Of Principle Study Of Lead Compound Demonstrating Inhibition Of Inflammatory Markers In White Blood Cells 7/1/2015
MediciNova, Inc. Announces The Completion Of Enrollment In Clinical Trial Of MN-166 (Ibudilast) In Alcohol Dependence 7/1/2015
Intralink-Spine Announces Long-Term Large-Animal Testing Shows Positive Results Related To Lower Back Pain 7/1/2015
Replicel Life Sciences Enrolls First Participant In Phase 1/2 Clinical Trial Of RCT-01 For Chronic Achilles Tendinosis 6/30/2015
Egalet Announces Top-Line Results From Oral Human Abuse Liability Study Of Egalet-002 6/30/2015
Aridis Pharmaceuticals Receives FDA Fast Track Designation For Aerucin For Treating Hospital-Acquired And Ventilator-Associated Pneumonia 6/30/2015
Immunovaccine Inc. Initiates Clinical Trial With DPX-RSV Vaccine 6/30/2015
SillaJen Publishes Clinical Data Demonstrating Safe Administration Of Multiple Intravenous Doses Of Oncolytic Virus In Patients With Metastatic Colorectal Cancer 6/29/2015
Egalet Jumps As Lead Drug Is Less Likely To Be Abused Than Other Painkillers 6/29/2015
RedHill Biopharma Ltd. (RDHL) Initiates Phase I/II Study Of ABC294640 For Refractory Lymphoma 6/29/2015
Comvita Human Intervention Trial Demonstrates Positive Effect Of Olive Leaf Extract On Cardiovascular Disease 6/29/2015
Bioiberica To Trial A New Compound On Human Subjects That Prevents Memory Loss In Patients With Mild Alzheimer's 6/29/2015
Adocia And Eli Lilly (LLY) Report Positive Phase 1b Topline Results On The Post-Meal Effect Of Ultra-Rapid Biochaperone Lispro In Patients With Type 1 Diabetes 6/29/2015
ProQR Therapeutics B.V. (PRQR) Announces Enrollment Has Started In Global Phase 1b Study Of QR-010 In Cystic Fibrosis Patients 6/26/2015
StemCells (STEM) Reports Top Line Results For Its Phase I/II Study In Dry Age Related Macular Degeneration 6/26/2015
Neos Therapeutics Presents Data At ASCP Annual Meeting For Investigational XR-ODT For Treatment Of ADHD 6/25/2015
CSL Behring Announces Pivotal Data Of Novel rVIII-SingleChain Therapy In Adolescents And Adults With Hemophilia A 6/24/2015
Agios (AGIO) Announces First Patient Dosed With AG-881 In Phase 1 Study In Patients With Advanced Solid Tumors With An IDH Mutation 6/24/2015
MediciNova, Inc. Announces Presentation Of Interim Data From Clinical Trial Of MN-166 (ibudilast) In Alcohol Dependence At The 38th Annual RSA (Research Society On Alcoholism) Scientific Meeting 6/24/2015
Catalyst Biosciences Announces Positive Results From A Phase 1 Clinical Trial Of Its Next Generation Coagulation Factor VIIa In Patients With Hemophilia A Or B And Preclinical Results From Its Factor IX And Factor Xa Programs 6/24/2015
AveXis Gains Orphan Drug Designation From European Medicines Agency For Gene Therapy Treatment In Spinal Muscular Atrophy 6/24/2015
Alnylam (ALNY) Reports New Positive Clinical Data For ALN-AT3, A Subcutaneously Administered, Investigational RNAi Therapeutic Targeting Antithrombin (AT) For The Treatment Of Hemophilia And Rare Bleeding Disorders 6/24/2015
NeuroRx Announces First Human Trial Results Targeting Sustained Treatment Of Bipolar Depression & Suicidality 6/24/2015
Vical  (VICL) Herpes Vaccine Clinical Trial Disappoints with "Confounding Results" 6/24/2015
Epizyme (EPZM) Surges on NHL Cancer Drug Data, As Analysts Laud Early Successes 6/24/2015
RestorGenex Announces Prostate Cancer Data On RES-529, A Dual TORC1/TORC2 Inhibitor 6/23/2015
TapImmune Inc. (TPIV) Reports Robust Immune Responses Generated In 19 Of 20 Evaluable HER2/Neu Breast Cancer Patients 6/23/2015
BIND Therapeutics (BIND) Announces FDA Authorization Of First-in-Human Clinical Trial With AstraZeneca PLC (AZN)’s Aurora B Kinase Inhibitor Accurin AZD2811 6/23/2015
ERYtech Pharma Announces Two Positive DSMB Reviews 6/23/2015
Epizyme (EPZM) Announces Additional Positive Data From Ongoing Phase 1 Study Of Tazemetostat (EPZ-6438) In Relapsed Or Refractory Non-Hodgkin Lymphoma 6/22/2015
Karyopharm (KPTI) Presents Hematologic Cancer Data On Lead Drug Candidate Selinexor At International Conference On Malignant Lymphoma 6/22/2015
ChromaDex, Inc. Announces A Collaborative Human Clinical Study On NIAGEN With The University of Colorado Boulder 6/18/2015
Admune Announces The First-In-Human Study Of Heterodimeric IL-15 (Hetil-15) With Broad Applications For Cancer Immunotherapy 6/18/2015
Heptares Announces Positive Outcome Of Phase 1A Study With First-Ever Selective Muscarinic M1 Receptor Agonist For Improving Cognition In Patients With Alzheimer's Disease 6/17/2015
Prothena (PRTA) Presents Clinical Results Demonstrating Robust, Rapid Reduction In Levels Of Free Serum Alpha-Synuclein Of Up To 96% After Single Dose Of PRX002, Novel Protein Immunotherapy For Parkinson's Disease 6/17/2015
Catabasis Pharmaceuticals, Inc. Initiates Movedmd, A Phase I/II Trial Of CAT-1004 For The Treatment Of Duchenne Muscular Dystrophy 6/17/2015
Sosei Subsidiary Heptares Announces Positive Outcome Of Phase 1a Study With First-Ever Selective Muscarinic M1 Receptor Agonist For Improving Cognition In Patients With Alzheimer's Disease 6/17/2015
Quartet Medicine Announces Neuron Publication Validating Role Of The BH4 Pathway In Chronic Neuropathic And Inflammatory Pain 6/17/2015
Minerva Neurosciences, Inc. (NERV) Provides Update On MIN-202, Selective Orexin-2 Receptor Antagonist 6/16/2015
XOMA (US) LLC (XOMA) Receives Orphan Drug Designation For XOMA 358 From FDA For Treatment Of Congenital Hyperinsulinism (HI) 6/16/2015
Neovacs SA Initiates Clinical Program In Dermatomyositis 6/16/2015
Phase I Data Published in The Lancet Show Boehringer Ingelheim's Idarucizumab Reverses Anticoagulant Effects of Dabigatran 6/16/2015
Apexigen Doses First Patient In Phase 1 Clinical Trial Of Its Immuno-Oncology Therapeutic Antibody APX005M 6/16/2015
Protalex, Inc. (PRTX) Receives Orphan Drug Designation From FDA For PRTX-100 To Treat Immune Thrombocytopenia 6/16/2015
PNP Therapeutics, Inc. Receives Orphan Drug Status For Gedeptin 6/16/2015
BioLife Solutions, Inc. (BLFS.OB) CryoStor Cited In New Journal Article On Results Of Phase I/II Clinical Trial Of Dendritic Cell Immunotherapy For Prostate Cancer 6/15/2015
EnGeneIC And Asbestos Diseases Research Institute Announce Encouraging Results From Mesomir-1 Phase 1 Trial In Late Stage Mesothelioma Patients 6/15/2015
Laurent Pharmaceuticals Announces Positive Phase 1b Topline Results For LAU-7b In Cystic Fibrosis 6/15/2015
Amarillo Biosciences (AMAR) Announces Presentation Of Eltoprazine Phase I/IIa Clinical Data At The 19th International Congress Of Parkinson's Disease And Movement Disorders 6/15/2015
Genzyme (GENZ) Initiates Phase I/II Clinical Trial to Evaluate Olipudase Alfa in Pediatric Patients 6/15/2015
Principia Biopharma Presents Full Phase 1 Clinical Trial Results For PRN1008, A Novel Reversible Covalent BTK Inhibitor, Supporting Further Clinical Development In Autoimmune And Inflammatory Diseases 6/15/2015
bluebird bio (BLUE) Reports New Beta-Thalassemia Major And Severe Sickle Cell Disease Data From HGB-205 Study At European Hematology Association 6/15/2015
Karyopharm (KPTI) Presents Hematologic Cancer Data On Lead Drug Candidate Selinexor At European Hematology Association Annual Meeting 6/15/2015
AbbVie (ABBV) Release: Phase 1b Study Of Investigational Treatment Venetoclax With Rituximab Shows Clinical Response In Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia 6/12/2015
Merrimack (MACK) Announces Expansion Of MM-398 (nal-IRI) Imaging Study To Patients With Metastatic Breast Cancer 6/12/2015
Calithera Biosciences, Inc. (CALA) Reports Phase I Data For CB-839 In Patients With Acute Leukemias At The 20th Congress Of The European Hematology Association 6/12/2015
TG Therapeutics, Inc. (MHA) To Present Clinical Data On TG-1101 And TGR-1202 At The 20th Congress Of The European Hematology Association And The 13th International Congress On Malignant Lymphoma 6/12/2015
Prothena (PRTA)'s NEOD001 Protein Immunotherapy Clinical Data Highlighted In Oral Presentation At The 20th Congress Of The European Hematology Association 6/12/2015
Cellectar Biosciences  (NVLT) Announces CLR1502 Development Program To Be Classified As Combination Product By FDA 6/12/2015
Agios (AGIO) Announces New Data from Ongoing Phase 1 Trial Of AG-120 Showing Durable Clinical Activity In Patients With Advanced Hematologic Malignancies 6/12/2015
Agios (AGIO) Announces New Data From Ongoing Phase 1 Dose Escalation And Expansion Trial Of AG-221 Showing Durable Clinical Activity In Patients With Advanced Hematologic Malignancies 6/12/2015
Corbus Announces FDA Orphan Drug Designation For Resunab For The Treatment Of Systemic Sclerosis (Scleroderma) 6/12/2015
Rock Creek Pharmaceuticals Announces Clinical Update 6/11/2015
ForSight VISION5's Clinical Data Demonstrating 6-Month IOP-Lowering From A Single Dose Presented At World Glaucoma Congress; Company Completes Enrollment Of Phase 2 Dose-Ranging Study 6/11/2015
Celyad Completes 30-Day Safety Follow-Up Of First Patient In NKG2D Phase I Trial 6/11/2015
Actinogen Limited Release: Excellent Research Progress With Xanamem – A Promising Alzheimers Drug 6/11/2015
Relmada Therapeutics Successfully Completes Phase 1 Single Ascending Dose Study With Promising NMDA Receptor Antagonist D-Methadone 6/10/2015
Xencor Reports Complete Data Results On Xmab5871 Program At European League Against Rheumatism (EULAR) 2015 Annual Meeting 6/10/2015
BerGenBio AS Initiates NSCLC Clinical Trial With BGB324 In Combination With erlotinib 6/10/2015
Prothena (PRTA) Announces First Human Dosed In Phase I Study Of PRX003 For The Treatment Of Psoriasis And Other Inflammatory Diseases 6/10/2015
FDA Awards Isarna Therapeutics Orphan Drug Designation For ISTH0036 To Improve Glaucoma Treatment Outcome 6/10/2015
Selecta Initiates Phase 1 Clinical Program Of SEL-212, Designed As The First Non-Immunogenic Biologic Treatment For Gout 6/10/2015
Arrowhead Research Corporation (ARWR) Receives Orphan Drug Designation For ARC-AAT 6/10/2015
Oncolytics Biotech Inc. (ONC.TO) Provides Update At AGM On Planned Registration Program For REOLYSIN 6/9/2015
Prothena (PRTA) To Present Clinical Results From Its Phase I Single Ascending Dose Study Of PRX002 At 19th International Congress Of Parkinson's Disease And Movement Disorders 6/8/2015
Celator Pharmaceuticals, Inc. Announces Expansion of Clinical Study In Patients With Untreated Myelodysplastic Syndrome (MDS) Or Acute Myeloid Leukemia (AML) At High-Risk Of Treatment-Related Mortality 6/8/2015
Merck's KEYTRUDA (pembrolizumab) Receives Conditional Approval In Canada For The Treatment Of Advanced Melanoma 6/8/2015
BeiGene Co.,Ltd Enrolls First Patient In Phase I Study Of BGB-A317, A Humanized Anti-PD-1 Monoclonal Antibody 6/8/2015
PhaseBio Announces Positive Data For Type 2 Diabetes Treatments PE0139 And PB1023 6/8/2015
Capricor Therapeutics, Inc. Announces Receipt Of FDA Clearance For The Phase I/II Study Of CAP-1002 For The Treatment Of Duchenne Muscular Dystrophy Related Cardiomyopathy 6/8/2015
Advaxis, Inc.'s Cancer Immunotherapy Delays Progression Of HER2+ Canine Osteosarcoma 6/8/2015
Osama Hamdy, MD PhD, Presented Results Of Metagenics Inc.' Ultra Glucose Control On Glucose Response And GLP-1 At American Diabetes Association 2015 6/8/2015
Asterias Biotherapeutics Announces First Patient Treated In Phase 1/2a Dose-Escalation Clinical Trial Of AST-OPC1 For Complete Cervical Spinal Cord Injury 6/8/2015
Dyax Corp. (DYAX) Presents Phase 1b DX-2930 Data At The 2015 European Academy of Allergology and Clinical Immunology Annual Congress 6/8/2015
Ligand Pharmaceuticals Inc. (LGND) Announces Favorable Results From Phase 1b Trial With LGD-6972 In Type 2 Diabetes And Plans To Initiate A Phase 2 Trial 6/8/2015
FDA Grants Breakthrough Designation to Genzyme (GENZ)’s Experimental ASMD Treatment 6/8/2015
Synageva BioPharma (GEVA) Completes Targeted Enrollment In Phase 1/2 Trial With SBC-103 For Mucopolysaccharidosis IIIB 6/5/2015
Retrophin (RTRX) Receives Fast Track Designation For RE-024 For The Treatment Of Pantothenate Kinase-Associated Neurodegeneration 6/5/2015
ASCO15 EXCLUSIVE: Berg’s Lead Cancer Drug May Shift Cancer Metabolism, Says CEO 6/4/2015
Regulus (RGLS) Initiates Phase I Clinical Study Of RG-012, A microRNA Therapeutic In Development For The Treatment Of Alport Syndrome 6/4/2015
Seattle Children's Opens Patient Enrollment For First Tumor Paint Clinical Trial For Children With Brain Cancer 6/4/2015
Gradalis Inc. Announces Presentation Of Data From A Pilot Study Of Vigil Cancer Vaccine In Ewing’s Sarcoma 6/4/2015
Catabasis Pharmaceuticals, Inc. Announces Preliminary Phase I Data For Hypercholesterolemia Product Candidate CAT-2054 6/4/2015
Catabasis Pharmaceuticals, Inc. Announces Preliminary Phase 1 Data For Hypercholesterolemia Product Candidate CAT-2054 6/4/2015
BEAT BioTherapeutics’ BB-R12 Provides Significant Improvement In Cardiac Function In Heart Failure Study 6/4/2015
Blaze Bioscience Inc. Announces Open Enrollment For Phase 1 Clinical Trial Of Tumor Paint BLZ-100 In Children With Brain Cancer 6/4/2015
Humanetics Granted FDA Clearance To Proceed With Cancer Treatment Study 6/3/2015
EXCLUSIVE: Nektar Therapeutics (NKTR), University of Texas MD Anderson Cancer Center Team Up on Phase 1/2 Trial of NKTR-214 6/2/2015
H. Lee Moffitt Cancer Center & Research Institute Announces First Patient In Nation Treated With KTE-C19 In Kite Pharma (KITE)'s Clinical Trial For Non-Hodgkin's Lymphoma 6/2/2015
Merrimack (MACK) Announces Data From An Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile For MM-398 In High-Grade Glioma 6/2/2015
Minervax Initiates Phase I Clinical Trial With Innovative Group B Streptococcal (GBS) Vaccine To Prevent Life-Threatening Infections In Newborns 6/2/2015
ASCO15: Dicerna (DRNA) Presents Preliminary Safety And Efficacy Data From DCR-MYC Phase 1 Study In Patients With Advanced Solid Tumors At The 2015 ASCO Annual Meeting 6/2/2015
ASCO15: Prothena (PRTA) Presents Compelling New Data From Ongoing Phase I/II Study Of NEOD001 In Patients With AL Amyloidosis At 2015 ASCO Annual Meeting 6/2/2015
ASCO15: Kite Pharma (KITE) Presents Clinical Biomarker Results in Patients Treated With Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy at the 2015 ASCO Annual Meeting 6/2/2015
ASCO15: Cleveland Biolabs Inc. (CBLI) Releases Entolimod Phase 1 Study Findings At ASCO 6/2/2015
Aphios Completes Enrollment In Phase I/II Clinical Trial Towards An HIV Cure 6/2/2015
Aptose Biosciences Granted Orphan Drug Designation By The U.S. FDA For APTO-253 In Acute Myeloid Leukemia 6/2/2015
Lipocine Inc. (LPCN) Receives FDA Orphan Drug Designation For LPCN 1107, An Oral Product Candidate For The Prevention Of Preterm Birth 6/2/2015
ASCO15: Merck & Co. (MRK) Findings Presented At 2015 ASCO Annual Meeting Add To Breadth Of KEYTRUDA (Pembrolizumab) Data; Anti-Tumor Activity Now Demonstrated In 13 Different Tumor Types 6/1/2015
ASCO15: ImmunoGen (IMGN)'s Mirvetuximab Soravtansine (IMGN853) Demonstrates Notable Single Agent Activity For Patients With Platinum-Resistant Ovarian Cancer 6/1/2015
Pharmacyclics (PCYC) Release: Ibrutinib (IMBRUVICA) Phase Ib/II Data Show Promise In Patients With Chronic Graft-Versus-Host-Disease 6/1/2015
ASCO15: Celsion Corporation (CLSN) Presents GEN-1 Immunotherapy Phase 1b Results In Recurrent Ovarian Cancer At ASCO 2015 6/1/2015
ASCO15: Calithera Biosciences, Inc. (CALA) Reports Phase I Data For CB-839 In Patients With Solid Tumors At The 2015 ASCO 6/1/2015
Astellas Pharma Inc. (ALPMY) Announces Preliminary Phase 1/2 Safety, Tolerability And Efficacy Data For ASP2215 In Patients With Relapsed Or Refractory Acute Myeloid Leukemia (AML) 6/1/2015